13D Filing: Viking Global and Arbutus Biopharma Corp (ABUS)

NAMES OF REPORTING PERSONS

Viking Global Investors LP

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a)
o

(b)
x

SOURCE OF FUNDS (see instructions)

OO (See Item 3)

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF SHARES

BENEFICIALLY OWNED BY
EACH REPORTING

PERSON WITH

SOLE VOTING POWER

0

SHARED VOTING POWER

0

SOLE DISPOSITIVE POWER

0

SHARED DISPOSITIVE POWER

16,013,540

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON

16,013,540

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

29.1%*

TYPE OF REPORTING PERSON

PN

The calculation assumes that there are a total of 55,051,995 Common Shares outstanding as of October 12, 2017,
as reported by Arbutus Biopharma Corporation (the “Issuer”) to Roivant Sciences Ltd. (“Roivant”).
This amount excludes 9,808,386 Common Shares underlying
500,000 shares of the Issuer’s series A participating convertible preferred shares (the “Preferred Shares”)
acquired by Roivant on October 16, 2017, which are not convertible into the Common Shares until they become mandatorily convertible
four years after October 16, 2017 (subject to adjustment and subject to limited exceptions in the event of certain transactions
or fundamental changes that would permit earlier conversion at Roivant’s option).